{
  "id": "5e30e9e3fbd6abf43b00003c",
  "type": "yesno",
  "question": "Is Ubrogepant effective for migraine?",
  "ideal_answer": "Yes, Ubrogepant is effective for treatment of migraine.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
    "http://www.ncbi.nlm.nih.gov/pubmed/30681821",
    "http://www.ncbi.nlm.nih.gov/pubmed/31800988",
    "http://www.ncbi.nlm.nih.gov/pubmed/31341711",
    "http://www.ncbi.nlm.nih.gov/pubmed/30242830",
    "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
    "http://www.ncbi.nlm.nih.gov/pubmed/29556965",
    "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
    "http://www.ncbi.nlm.nih.gov/pubmed/28645128",
    "http://www.ncbi.nlm.nih.gov/pubmed/30403405",
    "http://www.ncbi.nlm.nih.gov/pubmed/29136283",
    "http://www.ncbi.nlm.nih.gov/pubmed/30475090",
    "http://www.ncbi.nlm.nih.gov/pubmed/31758661",
    "http://www.ncbi.nlm.nih.gov/pubmed/31020659",
    "http://www.ncbi.nlm.nih.gov/pubmed/30995909"
  ],
  "snippets": [
    {
      "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Despite the clear safety concerns, clinical trial data suggests that their intermittent use remains a viable and safe alternative, with 2 molecules remaining in clinical development (ubrogepant and rimegepant). ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29556965",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two gepants, ubrogepant and rimegepant, have completed positive pivotal trials for acute treatment of migraine, but have not yet been submitted to the FDA for this indication.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30242830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Two gepants, ubrogepant and rimegepant, have completed positive pivotal trials for the acute treatment of migraine, but have not yet been submitted to the FDA for this indication. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30403405",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Area covered: This review reports on compounds currently under development for the oral treatment of acute migraine attacks, focusing on Calcitonin-Gene-Related-Peptide receptor antagonists, specifically ubrogepant and rimegepant. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30475090",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, new hope rises for the CGRP (calcitonin-gene related peptide)-antagonists, as the data for ubrogepant do not suggest hepatotoxicity but efficacy. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28645128",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We applied this strategy for another late-stage clinical program: ubrogepant (MK-1602), a novel oral calcitonin gene-related peptide receptor antagonist for acute treatment of migraine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29136283",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AIM: The aim of this trial was to evaluate the efficacy and tolerability of ubrogepant (MK-1602), a calcitonin gene-related peptide receptor antagonist (CGRP-RA), for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ubrogepant 100\u2009mg was significantly superior to placebo for two-hour pain freedom (25.5% vs 8.9%) but not for two-hour headache response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: This trial supports ubrogepant's efficacy and provides further evidence that CGRP-RAs are viable options for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Meanwhile, 1 small-molecule CGRP receptor antagonist (ubrogepant, MK-1602) is currently in phase 3 studies for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28644160",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CGRP receptor antagonists such as ubrogepant are effective for acute relief of migraine headache, whereas monoclonal antibodies against CGRP (eptinezumab, fremanezumab and galcanezumab) or the CGRP receptor (erenumab) effectively prevent migraine attacks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29691490",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recent findings\n\nCalcitonin gene-related peptide (CGRP) receptor antagonists (gepants-rimegepant and ubrogepant) and serotonin 5-HT __sub__ 1F __end_sub__  receptor agonists (ditans-lasmiditan) have completed phase 3 clinical trials and will soon offer novel, effective, well-tolerated nonvasoconstrictor options to treat acute migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31341711",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We applied this strategy for another late-stage clinical program: ubrogepant (MK-1602), a novel oral calcitonin gene-related peptide receptor antagonist for acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29136283",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently, orally administered next-generation small molecule CGRP-RAs have been shown to have safety and efficacy in acute treatment (ubrogepant and rimegepant) and prevention (atogepant) of migraine, giving additional CGRP-based therapeutic options for migraine patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31020659",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ubrogepant 100\u2009mg was significantly superior to placebo for two-hour pain freedom (25.5% vs 8.9%) but not for two-hour headache response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30995909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lasmiditan, rimegepant and ubrogepant will extend our therapeutic armamentarium for managing acute migraine attacks when triptans are not effective or contraindicated due to cardiovascular disorders.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30995909",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Lasmiditan, ubrogepant, and rimegepant are currently emerging acute migraine therapies that may be added to the arsenal of current migraine management.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30681821",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ubrogepant for the Treatment of Migraine .",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31800988",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ubrogepant 100\u2009mg was significantly superior to placebo for two-hour pain freedom (25.5% vs 8.9%) but not for two-hour headache response.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION\nThis trial supports ubrogepant's efficacy and provides further evidence that CGRP-RAs are viable options for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ubrogepant (MK-1602) is a novel, oral, calcitonin gene-related peptide receptor antagonist in clinical development with positive Phase III outcomes for acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31758661",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION: This trial supports ubrogepant's efficacy and provides further evidence that CGRP-RAs are viable options for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This trial supports ubrogepant's efficacy and provides further evidence that CGRP-RAs are viable options for the acute treatment of migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27269043",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Ubrogepant for the Treatment of Migraine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31800988",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Ubrogepant is an oral, small-molecule calcitonin gene-related peptide receptor antagonist for acute migraine treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31800988",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}